Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.50+0.04 (+1.16%)
Close on Nov 18, 2026Market cap $226.67MP/E –Yield –
Immuneering gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Immuneering's gross profit for the twelve months ending Dec 31, 2023 was $0, down 100.0% year over year. For fiscal 2023 it was $0, down 100.0% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $158.83K | -82.9% |
| FY2021 | Dec 31, 2021 | $926.89K | -10.1% |
| FY2020 | Dec 31, 2020 | $1.03M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $455 | – |
| Q3 FY2022 | Sep 30, 2022 | $19.04K | -92.8% |
| Q2 FY2022 | Jun 30, 2022 | $46.49K | -86.4% |
| Q1 FY2022 | Mar 31, 2022 | $92.85K | -72.6% |
| Q4 FY2021 | Dec 31, 2021 | -$16.63K | -108.7% |
| Q3 FY2021 | Sep 30, 2021 | $263.04K | -28.4% |
| Q2 FY2021 | Jun 30, 2021 | $341.44K | +40.1% |
| Q1 FY2021 | Mar 31, 2021 | $339.04K | – |
| Q4 FY2020 | Dec 31, 2020 | $191.85K | – |
| Q3 FY2020 | Sep 30, 2020 | $367.57K | – |
| Q2 FY2020 | Jun 30, 2020 | $243.77K | – |
See a number that looks wrong?